PrEP and PEP are Prevention Act

1) WHAT HAPPENED: On September 4, 2025, Rep. Waters (D-CA) introduced HR5127, the PrEP and PEP are Prevention Act, in the 119th Congress. The bill was referred to three committees (Energy and Commerce, Ways and Means, Oversight and Government Reform). As of April 30, 2026, the bill has 34 cosponsors—all Democrats—and remains in early committee stage. It has not received a hearing or markup. 2) THE MONEY TRAIL: This is a coverage mandate, not an appropriation. The bill does not authorize any direct federal spending. Instead, it forces private insurers, Medicare Part D, Medicaid, and federal employee plans to absorb the cost of PrEP/PEP drugs, administrative fees, lab monitoring, and counseling with no patient cost-sharing. The financial impact is a transfer from insurers' premium pools to drug manufacturers and lab providers. For insurers, the mandate increases medical loss ratios on PrEP-related claims. For manufacturers and labs, the removal of prior authorization and copays drives substantial volume growth. 3) STRUCTURAL WINNERS: Gilead ($GILD) is the clearest beneficiary—its branded PrEP portfolio (Descovy, Truvada) is the standard of care. The elimination of prior authorization removes a key barrier that plans used to steer patients to generics. Viatris ($VTRS) wins on generic PrEP volume—zero-cost coverage makes their drug the default for cost-conscious plans and patients. Labcorp ($LH) benefits from the mandated lab monitoring package (HIV testing, renal, STI panels) that must be covered at $0 copay for all PrEP users. Merck ($MRK) is a speculative beneficiary only if and when Islatravir receives FDA approval; the bill covers only approved drugs, so no current impact. 4) REAL MARKET DATA ANALYSIS: As of April 30, 2026, $GILD closed at $132.02, recovering from a 30-day decline of -5.27% and a recent low of $127.75 on April 27. The 7-day change is +1.24%, suggesting some momentum. $VTRS shows stronger near-term movement: +3.29% over 7 days and +11.55% over 30 days, closing at $15.07—near its 52-week high of $16.47. $LH is essentially flat (+0.16% 7-day, -0.97% 30-day) at $264.23. The divergence between GILD/VTRS (up) and LH (flat) suggests the market is more focused on drug volume than lab testing volume currently. 5) TIMELINE AND PATHETO PASSAGE: HR5127 is in early stages. Passage requires committee markup in three separate committees, House floor vote, Senate introduction and passage, and presidential signature. With 34 Democratic cosponsors and no Republican supporters, bipartisan traction is currently limited. The bill is unlikely to advance in the current divided Congress unless it gains Republican co-sponsors or is attached to a must-pass healthcare package (e.g., year-end omnibus). The straightforward mechanism (mandate, not new spending) improves its chances compared to complex health reforms.